Therapeutic application of canine adipose tissue-derived mesenchymal stromal cells in a dog with refractory immune-mediated thrombocytopenia, with diabetic ketoacidosis, and gastrointestinal bleeding induced by immunosuppressive treatment.

IF 2 3区农林科学 Q2 VETERINARY SCIENCES

Veterinary Research Communications Pub Date : 2025-08-28 DOI:10.1007/s11259-025-10849-y

Hee-Won Jang, Ga-Hyun Lim, So-Young Jeung, Jae-Gon Ah, Sung-Soo Kim

{"title":"Therapeutic application of canine adipose tissue-derived mesenchymal stromal cells in a dog with refractory immune-mediated thrombocytopenia, with diabetic ketoacidosis, and gastrointestinal bleeding induced by immunosuppressive treatment.","authors":"Hee-Won Jang, Ga-Hyun Lim, So-Young Jeung, Jae-Gon Ah, Sung-Soo Kim","doi":"10.1007/s11259-025-10849-y","DOIUrl":null,"url":null,"abstract":"<p><p>Refractory immune-mediated thrombocytopenia (ITP) in dogs is a condition with a poor prognosis due to the poor response to immunosuppressive therapy and the adverse effects of long-term drug administration. This case report describes the successful management of refractory ITP using stem cell therapy in a dog that experienced severe side effects from immunosuppressive treatment. The patient experienced recurrent relapses when prednisolone (PDS) tapering was attempted during conventional immunosuppressive therapy, necessitating prolonged use of PDS; this led to complications, such as diabetic ketoacidosis and chronic gastrointestinal bleeding. In this case, the dog was treated with canine adipose tissue-derived mesenchymal stromal cells (cAT-MSCs) administered intravenously at four-week intervals for eight sessions. Following MSC therapy, refractory ITP was successfully treated without PDS, and the side effects associated with prolonged use of PDS and multiple immunosuppressants were resolved. Although further investigations are needed for the clinical application of cAT-derived MSCs in ITP, cAT-MSC injections could be an alternative treatment option for refractory ITP in veterinary medicine.</p>","PeriodicalId":23690,"journal":{"name":"Veterinary Research Communications","volume":"49 5","pages":"294"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary Research Communications","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1007/s11259-025-10849-y","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Refractory immune-mediated thrombocytopenia (ITP) in dogs is a condition with a poor prognosis due to the poor response to immunosuppressive therapy and the adverse effects of long-term drug administration. This case report describes the successful management of refractory ITP using stem cell therapy in a dog that experienced severe side effects from immunosuppressive treatment. The patient experienced recurrent relapses when prednisolone (PDS) tapering was attempted during conventional immunosuppressive therapy, necessitating prolonged use of PDS; this led to complications, such as diabetic ketoacidosis and chronic gastrointestinal bleeding. In this case, the dog was treated with canine adipose tissue-derived mesenchymal stromal cells (cAT-MSCs) administered intravenously at four-week intervals for eight sessions. Following MSC therapy, refractory ITP was successfully treated without PDS, and the side effects associated with prolonged use of PDS and multiple immunosuppressants were resolved. Although further investigations are needed for the clinical application of cAT-derived MSCs in ITP, cAT-MSC injections could be an alternative treatment option for refractory ITP in veterinary medicine.

查看原文本刊更多论文

犬脂肪组织源性间充质细胞治疗免疫抑制治疗引起的难治性血小板减少症、糖尿病酮症酸中毒和胃肠道出血的犬

犬的难治性免疫介导性血小板减少症（ITP）是一种预后较差的疾病，由于免疫抑制治疗反应差和长期用药的不良影响。本病例报告描述了在免疫抑制治疗中经历严重副作用的狗中使用干细胞治疗难治性ITP的成功管理。在常规免疫抑制治疗中，当强的松龙（PDS）逐渐减少时，患者出现复发，需要长期使用PDS；这导致并发症，如糖尿病酮症酸中毒和慢性胃肠道出血。在这种情况下，狗被静脉注射犬脂肪组织来源的间充质间质细胞（cAT-MSCs），每隔四周进行八次治疗。MSC治疗后，难治性ITP成功治疗，无PDS，解决了长期使用PDS和多种免疫抑制剂相关的副作用。虽然cat来源的间充质干细胞在ITP中的临床应用还需要进一步的研究，但cAT-MSC注射可能是兽医学中难治性ITP的另一种治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary Research Communications 农林科学-兽医学

CiteScore

2.50

自引率

0.00%

发文量

173

审稿时长

3 months

期刊介绍： Veterinary Research Communications publishes fully refereed research articles and topical reviews on all aspects of the veterinary sciences. Interdisciplinary articles are particularly encouraged, as are well argued reviews, even if they are somewhat controversial. The journal is an appropriate medium in which to publish new methods, newly described diseases and new pathological findings, as these are applied to animals. The material should be of international rather than local interest. As it deliberately seeks a wide coverage, Veterinary Research Communications provides its readers with a means of keeping abreast of current developments in the entire field of veterinary science.